**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 28247**

**Manuscript Type: ORIGINAL ARTICLE**

***Basic Study***

***Ex vivo* response to mucosal bacteria and muramyl dipeptide in inflammatory bowel disease**

Loganes C *et al*. Cytokine response in IBD

Claudia Loganes, Erica Valencic, Alessia Pin, Elisa Marini, Stefano Martelossi, Samuele Naviglio, Luigina De Leo, Tarcisio Not, Lorenzo Monasta, Alberto Tommasini, Annalisa Marcuzzi

**Claudia Loganes, Elisa Marini, Samuele Naviglio, Tarcisio Not, Annalisa Marcuzzi**,Department of Medicine, Surgery, and Health Sciences, University of Trieste, Strada di Fiume, 447 Trieste, Italy

**Erica Valencic, Alessia Pin, Stefano Martelossi, Luigina De Leo, Tarcisio Not, Alberto Tommasini, Lorenzo Monasta,** **Tarcisio Not,** Institute for Maternal and Child Health– IRCCS “Burlo Garofolo”, I-34137 Trieste, Italy

**Author contributions:** Loganes C, Valencic E and Tommasini A designed the experimental plan and conceived and designed the research; Marini E, Pin A, De Leo L performed all experiments; Loganes C, Monasta L performed the statistical analyses; Martelossi S, Not T and Naviglio S enrolled the patients and provided patient samples; Loganes C, Tommasini A, Marcuzzi A wrote the paper; Marcuzzi A and Martelossi S revised the manuscript critically for important intellectual content; all authors read and approved the final version of this manuscript.

**Supported by** Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, No. RC 03/09.

**Institutional review board statement:** The study was reviewed and approved by the Institutional Review Board of the Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Trieste, Italy (RC 03/2009).

**Conflict-of-interest statement:** All the authors declare no conflict of interest.

**Data sharing statement:** Dataset available from the corresponding author at [alberto.tommasini@burlo.trieste.it](mailto:alberto.tommasini@burlo.trieste.it)

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to**: **Alberto Tommasini, MD, PhD,** Institute for Maternal and Child Health–IRCCS, Burlo Garofolo, Via dell’Istria 65/1, I-34137 Trieste, Italy. [alberto.tommasini@burlo.trieste.it](mailto:alberto.tommasini@burlo.trieste.it)

**Telephone**: +39-40-3785422

**Received:** June 28, 2016

**Peer-review started:** June 29, 2016

**First decision:** July 29, 2016

**Revised:** August 12, 2016

**Accepted:** September 6, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To evaluate how mucosal bacteria impact on the spontaneous and muramyl-dipeptide (MDP)-induced inflammation in Crohn’s disease (CD) and ulcerative colitis (UC).

***METHODS***

Colonic mucosal biopsies were collected from children with active or remissive CD, UC and controls. Two tissue samples were taken from inflamed mucosal segments (in patients with active disease) or from non-inflamed mucosa (in patients in remission or in healthy controls). Experiments were performed in the presence or absence of antibiotics, to assess whether the disease-associated microbiota can modulate the cytokine response *ex vivo*. For this purpose, each specimen was half-cut to compare spontaneous and MDP-induced inflammation in the presence of live bacteria or antibiotics. After 24 h of culture, an array of 17 cytokines was assessed in supernatants. Statistical analyses were performed to find significant differences in single cytokines or in patterns of cytokine response in the different groups.

***RESULTS***

We demonstrated that subjects with CD display a spontaneous production of inflammatory cytokines including granulocyte-colony stimulating factor **(**G-CSF), interleukin (IL)6, IL8, IL10 and IL12, that was not significantly influenced by the addition of antibiotics. UC specimens also displayed a trend of increased spontaneous secretion of several cytokines, which however was not significant due to broader variability among patients. After the addition of antibiotics, spontaneous IL8 secretion was significantly higher in UC than in controls.

In healthy controls, a trend towards the weakening of spontaneous IL6 or IL8 production was observed in the presence of live mucosal bacteria with respect to the presence of antibiotics. In contrast, in the presence of live bacteria UC showed an increasing trend of spontaneous IL8 production, while MDP stimulation resulted in lower IL8 production in the presence of antibiotics. We also showed that subjects with CD seem to have a lowered production of IL8 in response to MDP in the presence of live bacteria. Only with the addition of antibiotics, likely reducing the contribution of live bacteria, multivariate statistical analysis could identify the combination of measures of G-CSF, tumor necrosis factor alpha, IL4 and IL17 as a good discriminator between CD and UC.

***CONCLUSION***

We showed that the presence of live bacteria or antibiotics can significantly influence the inflammatory response *ex vivo* in inflammatory bowel diseases.

**Key words**: Crohn’s disease; Ulcerative colitis; Cytokines; Inflammation; Gut-microbiota

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Even though previous studies have already considered cytokine secretions as marker of an inflammatory condition and mucosal imbalance in Crohn’s disease (CD) subjects, they did not take into account the autochthonous colonization of the intestinal mucosa by the disease-associated microbiota. In this work we investigated whether the microbiota can modulate the *ex vivo* cytokine response, in the presence or absence of antibiotics, or if a selection of cytokines could discriminate different inflammatory bowel diseases types. Through a multivariate logistic model we identified, only in specimens treated with antibiotics, a specific cytokine profile able to discriminate CD from ulcerative colitis.

Loganes C, Valencic E, Pin A, Marini E, Martelossi S, Naviglio S, De Leo L, Not T, Monasta L, Tommasini A, Marcuzzi A. *Ex vivo* response to mucosal bacteria and muramyl dipeptide in inflammatory bowel disease. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Inflammatory bowel diseases (IBD) are intestinal disorders characterized by a complex inflammatory process that may involve any part of the digestive tract. IBD include mainly Crohn’s disease (CD) and ulcerative colitis (UC), which are characterized by a different spectrum of clinical and pathological features[1,2].

In CD, the inflammation is extended through the whole intestinal wall of the gut with a segmental distribution, while in UC the inflammatory process is continuous and predominantly confined to the colonic mucosa[2].

IBD are characterized by an aberrant activation of the mucosal immune system with reaction to luminal content in genetically susceptible subjects[3], resulting in a chronic inflammatory state with dysregulation of several cytokines[4-6].

Cytokines are ~~an~~ important mediators in the gut-associated immune system, both in physiological conditions and in disease[7]. In normal conditions, the mucosal immune activation reflects an active balance between tolerance of luminal content and response to commensal and pathogenic bacteria. Indeed, this basal activation is associated with a predominance of cytokines such as interleukin (IL) 10 and transforming growth factor beta (TGFβ) and the production of antimicrobial peptides that can contribute to the shaping of the “healthy” microbiota. In pathological conditions, other cytokines and mediators are produced, which can, at the same time, lead to tissue injury and altered regulation of the microbiota and dysbiosis[4,8-10].

Chronic tissue damage results in clinical intestinal symptoms in IBD patients (abdominal cramping and pain, diarrhea, constipation and bowel obstruction, nausea and vomiting), even though extra-intestinal manifestations (weight loss, fever, asthenia and arthralgias) and immune disorders are also associated with this pathologies[11].

Despite the large number of studies and clinical analyses, several issues remain to be solved regarding the immune pathogenesis of IBD. In particular, the therapy of IBD is still based mainly on anti-inflammatory and immunosuppressive therapies, while mounting evidence supports the idea that defective immunity may underlie IBD pathogenesis, especially in cases with an early onset in childhood[12]. In fact, excessive inflammation in IBD could either result from a hyper-response of the immune system or it may just represent a compensatory response to luminal contest in the background of defective immunity[13].

Indeed, CD has been alternatively classified as an autoinflammatory disorder or a disease with primary immune deficiency[14].

# On the one hand, some studies suggested that CD is an autoinflammatory disease, characterized by an increase in the inflammatory response due to nucleotide-binding oligomerization domain-containing protein 2 (NOD2) variants, even though data supporting this hypothesis are controversial. NOD2 is an intracellular receptor involved in gastrointestinal immunity; it detects bacterial components and has been identified as the first susceptibility gene for CD[15-17]. The binding of muramyl dipeptide (MDP) to NOD2 leads to the downstream activation of mitogen-activated protein (MAP) kinases and nuclear factor-kappa beta (NF-κB) signaling, which in turn stimulates the transcription of several immune response genes. However, early studies have shown the association of the most common mutation 3020*ins*C with a reduced activation of NF-κB[18]. In contrast, later investigations proposed that the pro-inflammatory action is caused by a dysregulated autophagy[19].

On the other hand, several studies have found evidence that CD patients present immune response defects. In fact, a decreased bacterial clearance by the phagocytic system has been observed in peripheral blood cells from patients with CD; furthermore, NOD2-/- mice exhibit a reduced production of antimicrobial peptides by Paneth cells that leads to an imbalance in the microbiota in the presence of certain microbial pathogens, and intestinal inflammation can be prevented in these models by the forced expression of defensins in the intestinal cells[20].

For these reasons, we wanted to describe what happens in the disease itself, not by using simple animal models, but by studying the relationships between the mucosal immune system, influenced by its multigenic background, and the intestinal microbiota colonizing the diseased epithelium.

In these conditions, we tried to understand how the inflammatory response to stimuli such as MDP is influenced *ex vivo* by the presence of live or antibiotic-inactivated bacteria.

We performed an *ex vivo* culture of colonic explants to investigate the mucosal response both in spontaneous conditions and after the stimulation with MDP.

**MATERIALS AND METHODS**

***Patients and gut biopsies collection***

Forty-eight children with IBD and eight control subjects were enrolled. Participation in the study was proposed to all patients with IBD or their guardians when the performance of a colonoscopy was needed for clinical assessment, required for the diagnosis or the follow-up of their intestinal disease.

Patients with IBD were divided into four groups based on the type of intestinal disorder and on endoscopic mucosal disease activity: active Crohn’s disease (CD, *n* = 23), remissive Crohn’s Disease (rCD, *n* = 3), active ulcerative colitis (UC, *n* = 15) and remissive ulcerative colitis (rUC, *n* = 7). Disease activity scores, namely the Pediatric Crohn’s Disease Activity Index (PCDAI) and the Pediatric Ulcerative Colitis Activity Index (PUCAI) were also calculated. Any other recent acute disease or chronic inflammatory conditions are reported in these patients.

Control subjects were selected among children who underwent colonoscopy as part of their clinical investigations for various reasons not related to inflammatory enteropathies, such as routine evaluation of juvenile intestinal polyps, autoimmune gastritis, unexplained abdominal symptoms and weight loss. They had evidence of normal, non-inflamed mucosa and were thus considered healthy controls (HC).

Colonic mucosal biopsies were taken during colonoscopy. For each subject, two specimens were collected from the same mucosal area, in addition to the biopsies obtained for clinical purposes. In patients with active disease, two inflamed biopsies were collected, while in patients with inactive disease or healthy controls two biopsies were taken from non-inflamed areas.

All subjects were recruited from the Gastroenterology and Clinical Nutrition Unit, Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Trieste, Italy and written informed consent was obtained from patients and donors (or their guardians) according to a protocol approved by the Independent Ethical Board at the Institute (n.185/08, 19/08/2008).

***Ex vivo specimen culture***

Immediately after collection, biopsies were cut in half following the intestinal layers’ orientation and split in two tubes containing a physiological saline solution. Once they reached the laboratory, the specimens were transferred to sterile tubes with culture medium (X-VIVO, Lonza, Verviers, Belgium) supplemented with 10% human AB serum (Sigma-Aldrich, Milano, Italy) and 2 mmol/L L-glutamine (EuroClone, Milano, Italy). The intestinal tissue was exposed to 250 ng/mL MDP (N-Acetylmuramyl-L-alanyl-D-isoglutamine hydrate, Sigma) or medium alone, in the presence or absence of antibiotics: 100 U/mL penicillin (EuroClone) and 0.1 mg/mL streptomycin (EuroClone).

After 24 h culture at 37 °C in a humidified atmosphere (95% air and 5%CO2), supernatants were collected and stored at -20 °C for cytokine analysis.

***Cytokine quantifications***

The cytokines and the chemokines released in the culture medium were measured using the Bio-Plex Pro® Human Cytokine 17-plex Assay (BioRad, Hemel Hempstead, United Kingdom), according to the manufacturer’s instructions.

Analytes examined by this method were IL1β, IL2, IL4, IL5, IL6, IL7, IL8, IL10, IL12 (p70), IL13, IL17, G-CSF, GM-CSF, IFNγ, MCP1 (MCAF), MIP1β, and TNFα.

Samples were analyzed with the Bio-Plex® 200 reader and data were managed using Bio-Plex Manager® software, which returned data as Median Fluorescence Intensity (MFI) and concentration (pg/mL).

***Statistical analysis***

All statistical analyses were carried out using Stata/IC 14.1 (StataCorp LP, College Station, United States) and GraphPad Prism software version 5 (GraphPad, San Diego, United States). Values assumed by cytokines were described as medians and interquartile ranges and represented with box plots using Tukey’s whiskers. Statistical significance was set as *P* < 0.05 (a), *P* < 0.01 (b) and *P* < 0.001 (c).

Associations between cytokines and specific conditions (HC *vs* IBD, and CD *vs* UC) were analyzed firstly by univariate logistic regression and then by multivariate logistic regression. For the multiple comparisons carried out by univariate logistic regression, considering the relatively small sample size, which implied having relatively large *P* values, we decided not to apply any correction to the p value for statistical significance: we realize that we carried out independent univariate logistic regressions on different outcomes and separately for 17 cytokines, chemokines and growth factors. However, this just is considered as a preliminary step for the selection of cytokines to be included in the multivariate analysis: significant variables (*P* < 0.05 in the univariate analysis) were entered into multivariate analysis. Multivariate logistic regression analysis was employed to determine cytokine profiles associated with the different forms of IBD. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of the multivariate models. The area under the curve, sensitivity and specificity were also calculated. For each model, we identified the optimal cut-off by maximizing the sum of sensitivity and specificity.

**RESULTS**

***Experimental design***

Clinical characteristics of all patients included in the study, obtained from the medical sheets and from the colonoscopy records, are reported in Supplementary Table 1 and Supplementary Table 2 and summarized in Table 1.

*Ex vivo* culture of biopsies is thought to reproduce both the immunological and the microbiologic background of the disease. However, to isolate the contribution of live bacteria to inflammation, biopsies were stimulated in absence or in presence of antibiotics. Thus, for each sample we examined four conditions: basal with live bacteria (LB) or with antibiotics (PS), and MDP-stimulated with (PS + MDP) or without antibiotics (LB + MDP).

After a 24 h culture, the media were harvested to proceed with the quantification of 17 analytes, including cytokines, chemokines and growth factors (Figure 1).

The levels of three cytokines (IL5, IL7 and IL13) were under the lower limit of detection (LLOD) in all evaluated conditions and were thus excluded.

***Basal cytokine network in IBD***

In basal conditions with live mucosal bacteria, five cytokines had levels significantly higher in CD than in controls (HC) (CD *vs* HC: G-CSF, *P* = 0.024, IL6 *P* = 0.037, IL8 *P* = 0.033, IL10 *P* = 0.049, IL12, *P* = 0.028); levels of most cytokines tended to be even higher in UC, but because of the high variability among patients, differences did not reach significance, except for GM-CSF, whose levels were higher in UC compared with both HC (*P* = 0.031) and CD (*P* = 0.034) (Figure 2).

Levels of IL1β, IL2, IL4, IL17, IFNγ, TNFα, MCP1 and MIP1β did not differ significantly between the three studied groups, even if median levels of several cytokines such as IL2, IL4 and TNFα tended to be higher in UC than in HC. In general, HC showed a narrower variability compared to patients (Supplementary Figure 1).

Median levels of all cytokines in the different groups and conditions are rendered in Figure 3 with a color analog scale (CAS): for each cytokine, values 0-24% of the higher value are displayed in green, 25%-49% in orange, 50%-74% in red and above 75% in dark red.

In specimens from patients with endoscopically inactive disease, almost all cytokines were detected, as expected, at lower levels than in active disease. The decrease is significant in UC for GM-CSF (*P* < 0.01), IL6 (*P* < 0.05), IL10 (*P* < 0.05) and TNFα (*P* < 0.05) (Data not shown).

The addition of antibiotics in the bioptic culture to inhibit mucosal bacteria did not lead to relevant changes in the secretion pattern (Supplementary Figure 2), with the exception of IL8 in UC samples. The trend of IL8 increase after antibiotics in UC is so clear that the difference compared with HC becomes significant (Figure 4).

***Cytokine network induced by Muramyl dipeptide***

Muramyl dipeptide was used to investigate the function of the NOD2-pathway *ex vivo* in CD compared with UC and HC.

In general, the response to MDP appeared to be higher in UC than in CD (see the CAS in Figure 3). After stimulation with MDP in the presence of live bacteria, even though the differences are not significant, there is a clear trend of increased secretion of IL2, IL6, IL8, IL17 and IFNγ in UC, while no change was observed in CD. Indeed, even if in a smaller scale, HC tended to secrete reduced amounts of IL2, IL6 and IFNγ (Figure 5).

However, after the addition of antibiotics, this pattern was subverted and MDP stimulation failed to produce an evident increase in cytokine secretion in any group and it was even possible to note a reduced trend of secretion for IL8 in UC (Figure 6).

No variation was noted in the remaining cytokines, whose values are reported in supplementary Tables 3 and 4.

***Multivariate logistic regression and ROC Analysis to identify profiles of pro-inflammatory cytokines associated with IBD diagnosis***

Multivariate logistic regression were carried out to assess if any cytokine combination was associated with IBD related outcomes.

Only experiments in the presence of antibiotics provided profiles significantly associated with IBD. In particular, without MDP stimulation, IL2, IL4 and IL8 were simultaneously associated with IBD in a multivariate analysis (Table 2). ROC analysis (Figure 7A) shows that the area under the curve (AUC) was 0.98 (95%CI: 0.93-1.00), and we could have a sensitivity of 100% with a specificity of 71%.

After MDP stimulation another set of cytokines (MCP1, IL8 and IL10) was significantly associated with IBD (Table 3). The AUC for this model was 0.91 (95%CI: 0.79-1.00) (Figure 7B). Keeping sensitivity for the detection of IBD at 94%, we obtained a specificity of 75%, which would permit to identify 45 IBD patients out of 48, with 2 false positives out of 8 healthy controls.

After MDP stimulation it was also possible to discriminate between CD and UC based on the measure of G-CSF, TNFα, IL4 and IL17 (Table 4). According to the ROC analysis (Figure 7C), the AUC was 0.78 (95%CI: 0.65-0.91), and we could obtain a sensitivity on CD of 92.31% with a specificity of 50%.

**DISCUSSION**

It is well known that subjects with active IBD display increased secretion of several inflammatory cytokines in the intestinal mucosa. For example, aberrant secretions of IL8 after challenge with *E. coli* or other intestinal bacteria were recorded by Edward and colleagues and considered as a marker of the mucosal imbalance typical of CD[21]. The authors, however, did not take into account the autochthonous colonization of the intestinal mucosa by the disease-associated microbiota. In the present work, we compared the cytokine profile of the intestinal mucosa in the presence or absence of antibiotics, to assess whether disease-associated microbiota can modulate the cytokine response *ex vivo*. We demonstrated that subjects with CD display a spontaneous production of inflammatory cytokines besides IL8, and including G-CSF, IL6, IL10 and IL12. The addition of antibiotics to the culture produced only a slight trend towards increased spontaneous cytokine secretion, both in CD and in UC, but no difference was significant, except for increased IL8 secretion in UC. These data may support the idea that antibiotics can influence UC, as suggested by other authors[22]. However, whilst some protocols that include metronidazole *in vivo* are shown to have protective effects on disease activity[22], other combinations had no effect[23]. Actually, it is well known that the risk of CD can be raised by previous use of antibiotics in childhood, but this is not believed to occur for UC[24]. Thus, the significance of increased levels of IL8 in UC after the addition of antibiotics remains without a clear explanation.

Even if the difference is not significant, there is a trend toward higher concentrations of inflammatory cytokines in UC if compared to CD. Actually, this is not surprising if we consider that we are sampling just superficial specimens where UC is expected to be more expressed than CD, which, on the contrary, may extend the inflammatory process throughout the whole intestinal wall[25].

Of note, in healthy controls, the inflammatory (IL6 or IL8) response with or without MDP is reduced in the presence of live bacteria if compared to antibiotics. This effect is likely due to a modulatory effect of live bacteria on ~~the~~ mucosal immunity. In contrast, samples from UC showed a trend of increase of cytokines such as IL6 and IL8 when stimulated with MDP in the presence of live bacteria. However, in the presence of antibiotics, stimulation with MDP was associated with decreased IL8 secretion. Thus, antibiotics alone seem to increase IL8 production in UC, either because of a loss of the protective effect of mucosal bacteria or for the release of pro-inflammatory bacterial compounds. Conversely, we observed a reduction of IL8 production in UC when MDP is used together with antibiotics. Even though there is no clear explanation for this phenomenon, we can argue that in this case antibiotics and MDP-induced peptides may synergize in controlling both protective and harmful bacteria[26].

We also showed that subjects with CD seem to have a lowered production of IL8 in response to MDP in the presence of live bacteria. Although it is not clear whether defects in NOD2 signaling might play a role in this finding, these results support the idea that CD is not usually associated with a hyper-inflammatory response to MDP, *i.e.,* it is not just an autoinflammatory disorder. Recent data suggest that inflammation in CD may be the result of compensatory responses to defective immunity[27].

Although it was not the primary aim of our work, we could demonstrate that culture with antibiotics is the only *ex vivo* condition in which it was possible to identify profiles of cytokine secretions able to discriminate between CD and UC with good sensitivity and specificity. Indeed, the combination of measures of G-CSF, TNFα, IL4 and IL17 was shown to identify CD with respect to UC with sensitivity and specificity respectively of 92% and 50%. Rather than being used to assist diagnosis, which relies only on clinical and histological features, these results highlight once more the importance of taking into account the presence of mucosal bacteria when dealing with *ex vivo* analyses of IBD.

Among the limitations of this study, we need to mention the small sample size. The decision not to apply corrections to the p values for significance for multiple univariate comparisons was a consequence of this constrain and it should be taken into account.

However, despite the small sample size, valid results have been obtained with this *ex vivo* mucosal culture, that allowed us to discern the two IBD forms.

In conclusion, we showed that CD and UC have distinct cytokine profiles in the intestinal mucosa and that the mucosal-associated microbiota can differentially impact on the inflammatory response in the two conditions.

**COMMENTS**

***Background***

Inflammatory bowel disease is associated with an unbalanced crosstalk between the mucosal immune system and the luminal content. Production of cytokines and antimicrobial-peptides in gut mucosa may contribute to the shaping of an altered intestinal microbiota and, conversely, microbes can translocate across the epithelium and induce an excessive inflammatory response and recruit adaptive immunity. Treatment of inflammatory bowel diseases (IBD) with antibiotics, however, gave inconsistent results as different bacterial species may have protective or harmful effects.

***Research frontiers***

Studies on the pathogenesis of IBD should involve the specific disease-associated microbiota together with the mucosal immunity, with its genetic background. Thus, *ex vivo* experiments that bring together these two factors are of particular importance to unravel the pathogenesis of IBD.

***Innovations and breakthroughs***

By reproducing four different conditions, we could dissect the effect of disease–associated live or antibiotic-inactivated bacteria on the mucosal response to muramyl dipeptide (MDP). We showed that live bacteria affect the response to MDP in different ways in Crohn’s disease (CD) and in ulcerative colitis (UC).

***Applications***

*Ex vivo* analyses of the inflammatory response in the presence of antibiotics and soluble stimuli may allow studying the action of different antibiotics in patients with CD or UC.

***Terminology***

MDP represents a pro-inflammatory stimulus used to mimic the inflammatory activation.

***Peer-review***

Some strengths of the article include: an adequate sample to test the hypothesis, novel study looking at the autochthonous colonization of the intestinal mucosa by the disease-associated microbiota, and seemingly good methods to address the question. It also provides and a novel method to identify CD and UC based off of specific cytokines markers.

**REFERENCES**

1 **Vermeire S**. Towards a novel molecular classification of IBD. *Dig Dis* 2012; **30**: 425-427 [PMID: 22796810 DOI: 10.1159/000338147]

2 **Vermeire S**, Van Assche G, Rutgeerts P. Classification of inflammatory bowel disease: the old and the new. *Curr Opin Gastroenterol* 2012; **28**: 321-326 [PMID: 22647554 DOI: 10.1097/MOG.0b013e328354be1e]

3 **Nagalingam NA**, Lynch SV. Role of the microbiota in inflammatory bowel diseases. *Inflamm Bowel Dis* 2012; **18**: 968-984 [PMID: 21936031 DOI: 10.1002/ibd.21866]

4 **Sanchez-Munoz F**, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. *World J Gastroenterol* 2008; **14**: 4280-4288 [PMID: 18666314 DOI: 10.3748/wjg.14.4280]

5 **Baumgart DC**, Sandborn WJ. Crohn's disease. *Lancet* 2012; **380**: 1590-1605 [PMID: 22914295 DOI: 10.1016/S0140-6736(12)60026-9]

6 **Geremia A**, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. *Autoimmun Rev* 2014; **13**: 3-10 [PMID: 23774107 DOI: 10.1016/j.autrev.2013.06.004]

7 **Kleiner G,** Zanin V, Monasta L, Crovella S, Caruso L, Milani D, Marcuzzi A. Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17. *Exp Ther Med* 2015; **9**: 2047-2052 [PMID: 26136934 DOI: 10.3892/etm.2015.2370]

8 **Strober W**, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 1756-1767 [PMID: 21530742 DOI: 10.1053/j.gastro.2011.02.016]

9 **Manoharan I**, Suryawanshi A, Hong Y, Ranganathan P, Shanmugam A, Ahmad S, Swafford D, Manicassamy B, Ramesh G, Koni PA, Thangaraju M, Manicassamy S. Homeostatic PPARα Signaling Limits Inflammatory Responses to Commensal Microbiota in the Intestine. *J Immunol* 2016; **196**: 4739-4749 [PMID: 27183583 DOI: 10.4049/jimmunol.1501489]

10 **Al Nabhani Z**, Lepage P, Mauny P, Montcuquet N, Roy M, Le Roux K, Dussaillant M, Berrebi D, Hugot JP, Barreau F. Nod2 Deficiency Leads to a Specific and Transmissible Mucosa-associated Microbial Dysbiosis Which Is Independent of the Mucosal Barrier Defect. *J Crohns Colitis* 2016; Epub ahead of print [PMID: 27147452 DOI: 10.1093/ecco-jcc/jjw095]

11 **de Souza HS**, Fiocchi C. Immunopathogenesis of IBD: current state of the art. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 13-27 [PMID: 26627550 DOI: 10.1038/nrgastro.2015.186]

12 **Bianco AM**, Zanin V, Girardelli M, Magnolato A, Martelossi S, Tommasini A, Marcuzzi A, Crovella S. A common genetic background could explain early-onset Crohn's disease. *Med Hypotheses* 2012; **78**: 520-522 [PMID: 22309886 DOI: 10.1016/j.mehy.2012.01.02]

13 **Notarangelo LD**, Tommasini A. Defective and excessive immunities in pediatric diseases. *Curr Pharm Des* 2012; **18**: 5729-5734 [PMID: 22726115 DOI: 10.2174/138161212803530943]

14 **Tontini GE**, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. *World J Gastroenterol* 2015; **21**: 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21]

15 **Hugot JP**, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 2001; **411**: 599-603 [PMID: 11385576 DOI: 10.1038/35079107]

16 **Ogura Y**, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 2001; **411**: 603-606 [PMID: 11385577 DOI: 10.1038/35079114]

17 **Naser SA**, Arce M, Khaja A, Fernandez M, Naser N, Elwasila S, Thanigachalam S. Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis. *World J Gastroenterol* 2012; **18**: 412-424 [PMID: 22346247 DOI: 10.3748/wjg.v18.i5.412]

18 **Cho JH**. The Nod2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease. *Inflamm Bowel Dis* 2001; **7**: 271-275 [PMID: 11515855 DOI: 10.1097/00054725-200108000-00014]

19 **Stappenbeck TS**, Rioux JD, Mizoguchi A, Saitoh T, Huett A, Darfeuille-Michaud A, Wileman T, Mizushima N, Carding S, Akira S, Parkes M, Xavier RJ. Crohn disease: a current perspective on genetics, autophagy and immunity. *Autophagy* 2011; **7**: 355-374 [PMID: 20729636 DOI: 10.4161/auto.7.2.13074]

20 **Biswas A**, Liu YJ, Hao L, Mizoguchi A, Salzman NH, Bevins CL, Kobayashi KS. Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum. *Proc Natl Acad Sci U S A* 2010; **107**: 14739-14744 [PMID: 20679225 DOI: 10.1073/pnas.1003363107]

21 **Edwards LA**, Lucas M, Edwards EA, Torrente F, Heuschkel RB, Klein NJ, Murch SH, Bajaj-Elliott M, Phillips AD. Aberrant response to commensal Bacteroides thetaiotaomicron in Crohn's disease: an ex vivo human organ culture study. *Inflamm Bowel Dis* 2011; **17**: 1201-1208 [PMID: 21484962 DOI: 10.1002/ibd.21501]

22 **Sato K**, Chiba T, Ohkusa T. Serial changes of cytokines in active ulcerative colitis: effects of antibiotic combination therapy. *Hepatogastroenterology* 2009; **56**: 1016-1021 [PMID: 19760932 DOI: 10.1016/S0016-5085(09)61192-6]

23 **Mantzaris GJ**, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. *Am J Gastroenterol* 1997; **92**: 454-456 [PMID: 9068468]

24 **Ungaro R**, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, Shaw S, Van Kruiningen H, Colombel JF, Atreja A. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. *Am J Gastroenterol* 2014; **109**: 1728-1738 [PMID: 25223575 DOI: 10.1038/ajg.2014.246]

25 **Abraham C**, Cho JH. Inflammatory bowel disease. *N Engl J Med* 2009; **361**: 2066-2078 [PMID: 19923578 DOI: 10.1056/NEJMra0804647]

26 **Reinoso Webb C**, Koboziev I, Furr KL, Grisham MB. Protective and pro-inflammatory roles of intestinal bacteria. *Pathophysiology* 2016; **23**: 67-80 [PMID: 26947707 DOI: 0.1016/j.pathophys.2016.02.002]

27 **Marks DJ**, Rahman FZ, Sewell GW, Segal AW. Crohn's disease: an immune deficiency state. *Clin Rev Allergy Immunol* 2010; **38**: 20-31 [PMID: 19437144 DOI: 10.1007/s12016-009-8133-2]

**P-Reviewer:** Kojima N **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Italy

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0




**Figure 1 Schematic culture protocol of colonic biopsies derived from colonoscopy.** LB: Live Bacteria; PS: Penicillin-streptomicin; MDP: Muramyl dipeptide.




**Figure 2** **Cytokine secretion levels by colonic biopsies from inflammatory bowel diseases patients.** Levels of cytokine secretion by colonic biopsies from inflammatory bowel diseases (IBD) patients in active phase (Crohn’s Disease, CD; Ulcerative Colitis, UC) and healthy controls (HC) in basal condition (LB, Live Bacteria). Statistical significances are denoted using alphabetical letters (a*P* < 0.05).




**Figure 3 Color analog scale representing the median levels of all cytokines analyzed.** Median levels of all cytokines in healthy controls (HC), Crohn’s disease (CD) and ulcerative colitis (UC) groups in the four experimental conditions: live bacteria (LB), antibiotics (PS), live bacteria + Muramyl dipeptide (LB+MDP) and antibiotics + MDP (PS+MDP). For each cytokine, values 0-24% of the higher value are displayed in green, 25%-49% in orange, 50%-74% in red and above 75% in dark red. Asterisks indicate the set of cytokines whose measure allow to discriminate CD from UC with 92% sensitivity and 50% specificity.




**Figure 4** **Dosage of IL8 secretion by colonic biopsies from inflammatory bowel diseases patients**. Levels of IL8 secretion by colonic biopsies from patients with active Crohn’s Disease (CD), active Ulcerative Colitis (UC) and from healthy controls (HC), in the presence (+PS) or absence (-PS, Live Bacteria) of antibiotic mixture. Statistical significances are denoted using alphabetical letters (b*P* < 0.01).



**Figure 5 Representative trend of cytokine secretion after muramyl-dipeptide stimulation, with live bacteria.** Variation trend of IL6 secretion after muramyl-dipeptide (MDP) stimulation in patients suffering from active Crohn’s disease (CD), active ulcerative colitis (UC) and healthy controls (HC), in absence of antibiotics (Live Bacteria, LB). No statistical significance was found.



**Figure 6 Representative trend of cytokine secretion after muramyl-dipeptide stimulation, with antibiotics.** Variation trend of IL8 secretion after muramyl-dipeptide (MDP) stimulation in patients suffering from active Crohn’s disease (CD), active ulcerative colitis (UC) and healthy controls (HC), in presence of antibiotics (+PS). No statistical significance was found.



**Figure 7** **Multivariate combinations.** A: Roc curve of IL2, IL4 and IL8: the best cutoff value was for a sensitivity of 100% and specificity of 71% to discriminate IBD (UC and CD) from healthy controls (AUC = 0.98, 95%CI: 0.93–1.00); B: Roc curve of MCP1, IL8 and IL10: the best cutoff value was for a sensitivity of 94% and specificity of 75% to discriminate IBD (UC and CD) from healthy controls (AUC = 0.91, 95%CI: 0.79–1.00); C: Roc curve of G-CSF, TNFα, IL4 and IL17: the best cutoff value was for a sensitivity of 92% and specificity of 50% to discriminate CD from UC (AUC = 0.78, 95%CI: 0.65-0.91).

**Table 1 Characteristics of patients included in the study**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Patients (*n* = 56)** |  | **Age (yr) (mean ± SD)** | **Male/female** | **Active/remission** |
| IBD (*n* = 48) | CD (*n* = 26) | 11 ± 3.08 | 16/10 | 23/3 |
| UC (*n* = 22) | 15 ± 3.88 | 12/10 | 15/7 |
| CONTROLS (*n* = 8) | HC (*n* = 8) | 10 ± 4.60 | 4/4 | - |

IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; HC: Healthy controls.

**Table 2 Multivariate logistic model for inflammatory bowel disease patients *vs* healthy controls in the presence of antibiotics and without muramyl-dipeptide stimulation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **OR** | **95%CI** | ***P* value** | **Regression coefficients** |
| IL2 | 1.553421 | 1.011162 – 2.386481 | 0.044 | 0.440460 |
| IL4 | 0.473238 | 0.228780 – 0.978906 | 0.044 | -0.748157 |
| IL8 | 1.000267 | 1.000030 – 1.000504 | 0.027 | 0.000267 |
| Constant | 0.065259 | 0.003533 – 1.205600 | 0.067 | -2.729393 |

**Table 3 Multivariate logistic model for inflammatory bowel disease patients *vs* healthy controls in the presence of antibiotics and muramyl-dipeptide stimulation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **OR** | **95% CI** | ***P* value** | **Regression coefficients** |
| MCP1 | 0.997248 | 0.995067 – 0.999434 | 0.014 | -0.0027555 |
| IL8 | 1.000094 | 1.000019 – 1.000170 | 0.014 | 0.0000944 |
| IL10 | 1.098966 | 1.009008 – 1.196944 | 0.030 | 0.0943694 |
| Constant | 0.529026 | 0.108222 – 2.586054 | 0.432 | -0.636717 |

**Table 4 Multivariate logistic model for Crohn’s disease *vs* ulcerative colitis in the presence of antibiotics and muramyl-dipeptide stimulation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **OR** | **95%CI** | ***P* value** | **Regression coefficients** |
| G-CSF | 0.999703 | 0.999484 – 0.999921 | 0.008 | -0.0002975 |
| TNFα | 0.990492 | 0.981420 – 0.999649 | 0.042 | -0.0095533 |
| IL4 | 1.155281 | 1.012918 – 1.317651 | 0.031 | 0.1443433 |
| IL17 | 1.009361 | 1.000308 – 1.018497 | 0.043 | 0.0093177 |
| Constant | 1.043247 | 0.333344 – 3.264992 | 0.924 | 0.042338 |